Home > Companies > QuVa Pharma, Inc

QuVa Pharma, Inc

quvapharma.com

QuVa Pharma, Inc. is a newly-formed national platform for sterile compounding pharmacy services led by two experienced industry executives that has received a majority equity commitment from Bain Capital Private Equity to support the company’s creation and expansion plans. As part of its formation, QuVa Pharma has acquired the assets of the compounding services division of a company leader in the field of parenteral and management services, including its state-of-the-art 503B manufacturing facility in Sugar Land, Texas.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

National Medtech & Biotech Summit 2024

Conference

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

Related News

UROGEN PHARMA ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

Business Wire | March 06, 2020

UroGen Pharma Ltd. a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) to seventy-six new employees in connection with their employment with Urogen. These new team members will support the Company as it prepares for potential approval and commercial launch of its first product candidate....

Pharma Tech

IACTA PHARMACEUTICALS AND TALLC CORPORATION ANNOUNCE STRATEGIC COLLABORATION TO UTILIZE NOVEL SMARTCELLE TOPICAL DELIVERY TECHNOLOGY

IACTA Pharmaceuticals, Inc. | December 16, 2021

IACTA Pharmaceuticals, Inc. an innovation leader in ophthalmic therapeutics, and TALLC Corporation Inc. a pioneering ophthalmology company focused on the growing unmet needs of patients with corneal and retinal conditions, announced that they are entering into a strategic collaboration and licensing agreement. The agreement grants IACTA the use of TALLC’s proprietary SmartCelle™ micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development. IACTA...

HOW EHR-INTEGRATED PDMPS INCREASE INTEROPERABILITY, DECREASE BURDEN

EHRIntelligence | March 11, 2020

A prescription drug monitoring program (PDMP) that is implemented into the EHR can decrease the strenuous process of checking the PDMP, thus reducing the cognitive workload and burden for the clinician. However, only one-in-three hospitals can access PDMP data within its EHR system. PDMPs are state-run electronic databases that have been deployed in 49 states, excluding Missouri. The program collects data from pharmacies on Drug Enforcement Agency (DEA) controlled substances and prescription dru...

Business Insights

LTS TAKES NEXT STEP IN ITS GROWTH JOURNEY WITH THE ACQUISITION OF TAPEMARK INC.

LTS Lohmann Therapie-Systeme AG | August 23, 2022

LTS LOHMANN Therapie-Systeme AG announces the closing of the acquisition of Tapemark Inc. located in St. Paul, MN, USA. This acquisition combines Tapemark, a world-class CDMO specialized in transdermal drug delivery systems and oral thin films as well as unit dose semi-solid drug and iontophoresis products with LTS, a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches Oral Thin Films and Micro Array Patches (MAP) ...